PLAB

Photronics is a high-quality, fortress-balance-sheet niche supplier trading like a tired cyclical. Liabilities/equity is just 0.18x, cash is $492M (~27% of the $1.85B market cap), and long-term debt is a rounding error. Net income has climbed every year for five straight years ($55M→$119M→$125M→$131M→$136M), net margin is up to 16.1%, and management returned $97.4M via buybacks in FY2025 (5.0M shares at $19.52, now $31.28 — well-timed) while shrinking the share count 6.7%. At 13.7x trailing EPS of $2.28 — closer to ~10x once you net out the cash hoard — and 2.2x sales, the price already discounts a fair amount of pessimism, which is what creates the opportunity.

The honest caveat is that the top line has gone backwards for two years: revenue peaked at $892M in FY2023 and has slipped to $867M then $849M (-2.0% YoY). More telling, gross profit fell 5.1% and operating income fell 6.0%, so the +4.4% net-income gain came from below the operating line (interest income on the cash pile, tax/FX), not operating leverage — lower-quality growth, and the +9.1% EPS print leans heavily on buybacks. The MD&A is blunt about the cyclicality: photomask demand tracks new design activity, not chip volumes, and downturns bring 'accelerated erosion of selling prices.' Capex jumped 43.7% to $188M, compressing free cash flow to roughly $60M and drawing cash down 17.7%.